Search

Background: Multimodal Neuro-Monitoring advances the treatment of patients through continuous monitoring of different parameters and generates high volumes of electronically available data [ref:1]. One possibility to analyze this “tsunami” of data is Visual Analytics (VA) which[for full text, please go to the a.m. URL], 64. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS)

A Task Force was convened by the EFNS/MDS-ES Scientist Panel on Parkinson's disease (PD) and other movement disorders to systemically review relevant publications on the diagnosis of PD.Following the EFNS instruction for the preparation of neurological diagnostic guidelines, recommendation levels have been generated for diagnostic criteria and investigations.For the clinical diagnosis, we recommend the use of the Queen Square Brain Bank criteria (Level B). Genetic testing for specific mutations is recommended on an individual basis (Level B), taking into account specific features (i.e. family history and age of onset). We recommend olfactory testing to differentiate PD from other parkinsonian disorders including recessive forms (Level A). Screening for pre-motor PD with olfactory testing requires additional tests due to limited specificity. Drug challenge tests are not recommended for the diagnosis in de novo parkinsonian patients. There is an insufficient evidence to support their role in the differential diagnosis between PD and other parkinsonian syndromes. We recommend an assessment of cognition and a screening for REM sleep behaviour disorder, psychotic manifestations and severe depression in the initial evaluation of suspected PD cases (Level A). Transcranial sonography is recommended for the differentiation of PD from atypical and secondary parkinsonian disorders (Level A), for the early diagnosis of PD and in the detection of subjects at risk for PD (Level A), although the technique is so far not universally used and requires some expertise. Because specificity of TCS for the development of PD is limited, TCS should be used in conjunction with other screening tests. Conventional magnetic resonance imaging and diffusion-weighted imaging at 1.5 T are recommended as neuroimaging tools that can support a diagnosis of multiple system atrophy (MSA) or progressive supranuclear palsy versus PD on the basis of regional atrophy and signal change as well as diffusivity patterns (Level A). DaTscan SPECT is registered in Europe and the United States for the differential diagnosis between degenerative parkinsonisms and essential tremor (Level A). More specifically, DaTscan is indicated in the presence of significant diagnostic uncertainty such as parkinsonism associated with neuroleptic exposure and atypical tremor manifestations such as isolated unilateral postural tremor. Studies of [(123) I]MIBG/SPECT cardiac uptake may be used to identify patients with PD versus controls and MSA patients (Level A). All other SPECT imaging studies do not fulfil registration standards and cannot be recommended for routine clinical use. At the moment, no conclusion can be drawn as to diagnostic efficacy of autonomic function tests, neurophysiological tests and positron emission tomography imaging in PD.The diagnosis of PD is still largely based on the correct identification of its clinical features. Selected investigations (genetic, olfactory, and neuroimaging studies) have an ancillary role in confirming the diagnosis, and some of them could be possibly used in the near future to identify subjects in a pre-symptomatic phase of the disease.

Critical Care Medicine is a relatively young and high-tech branch in modern medicine that combines clinical skills, powerful drugs and sophisticated mechanical devices to support the function of vital organs. This allows patients to survive a variety of previously lethal insults such asmultiple trauma, extensive surgery or severe infections. Despite this dedicated care, mortality among critically ill patients who require intensive care for more than a few days remains around 20% worldwide. Critical illness affects millions of patients each year worldwide, and consumesa large fraction of health care resources. It is therefore of great interest to detect those patients most vulnerable to specific organ deterioration as early as possible, in order to administer dedicated therapies earlier and hopefully prevent the chronic and lethal phases of critical illness. The typical ICU generates vast amounts of data from several monitoring systems for each patient. At the department of Intensive Care Medicine of the university hospital Leuven, this data is electronically collected as time series of varying resolutions and integrated in apatient data management system (PDMS). Using data mining and machine learning techniques, clinically relevant prediction models have already been developed from the PDMS data. It is now the time to transition early detection models into intelligent warning systems to be used for decision support by the physician, on the daily evaluation of the individual ICU patients. With the help of an interdisciplinary research team, I will conduct my PhD first by acquiring the knowledge and skills required to perform in-depth analysis of clinical and research databases collected at Leuven hospital ICU or gathered in international collaboration with other ICU's. Second, I will develop novel models for early detectionof organ-specific critical illness. Finally, the ultimate goal will be to translate these models into bedside tools to be used at the bedside of the ICU patient, and to validate them in a prospective observational clinical trial. status: published

Critically ill patients are patients who, due to a variety of triggering medical conditions, require vital organ support to avoid imminent death. Despite major progress in intensive care the patients still face a high mortality risk. Moreover, critical illness is hallmarked by features of accelerated aging where many patients experience an adverse legacy of the illness long after hospital discharge. This is mostly described for adults and includes muscle weakness, chronic renal failure despite resolution of acute renal damage, bone loss and fracture risk, neurocognitive impairment and post-traumatic stress disorders. Children, treated in the paediatric intensive care unit (PICU) during crucial developmental phases, show impaired long-term physical and neurocognitive/psychological development and reduced quality of life. The degree to which the developmental impairment was already present or predestined at PICU admission, how much of the legacy was evoked by critical illness and its management, and what the underlying biological mechanisms are, remained unclear. The main objective of this doctoral thesis was thus to gain more insight in the underlying biological processes and modifiable risk factors with regard to the long-term developmental deficit faced by critically ill children. We hypothesised that two intensive care-related interventions during PICU stay could potentially affect the long-term outcome of these critically ill children. These are the exposure to phthalates, which are toxic plasticisers shown to leach from indwelling medical devices, and the nutritional management early during the course of critical illness. We further hypothesised that this legacy of critical illness and its management could be brought about by damage-related changes in DNA methylation or by telomere length alterations. In a first part, we documented the impact of exposure to circulating phthalates during paediatric critical illness on long-term neurocognitive outcome of critically ill children. We demonstrated that plasma concentrations of several phthalate metabolites, which were virtually undetectable in healthy children, were extremely high in critically ill children upon PICU admission. They decreased rapidly, but remained markedly elevated at PICU discharge. Moreover, exposure to circulating phthalate metabolites was independently and robustly associated with the attention deficit observed years after PICU admission. These data underscore the importance to use, whenever possible, medical devices composed of alternative, safer plasticisers or with low phthalate release potential. In a second part, we focused on the nutritional management during PICU stay. Providing artificial nutritional support is thought to be of major importance in an intensive care setting, as the vast majority of critically ill patients are unable to eat normally, particularly while being mechanically ventilated. Observational data have associated malnutrition during critical illness with muscle wasting, weakness and delayed recovery. Consequently, many clinicians have assumed that artificial nutrition via the parenteral route is beneficial for patients' outcome. However, a large randomised controlled clinical study (the "PEPaNIC" trial) showed that withholding of such supplemental parenteral nutrition during the first week of paediatric intensive care reduced the incidence of new infections and accelerated recovery, allowing an earlier PICU discharge. Despite these beneficial short-term effects, concerns have been raised about long-term developmental consequences, possibly mediated by DNA methylation changes or telomere length alterations, of tolerating such a macronutrient deficit. Hence, assessment of the impact on long-term outcome of the children was crucial. In this second part we therefore documented the impact of critical illness and of early initiation of supplemental parenteral nutrition on telomere length alterations and DNA methylation changes during PICU stay, and on long-term health risks, and physical and neurocognitive outcome of PICU survivors. As accelerated telomere shortening could theoretically explain part of the legacy of paediatric critical illness, we quantified telomere length in repeated white blood cell DNA harvested in PICU from patients who were enrolled in the PEPaNIC-trial, as compared with healthy children who never needed intensive care. We found that shorter than normal leukocyte telomeres are present in critically ill children admitted to the PICU. Duration of stay in PICU and early initiation of parenteral nutrition further shortened telomeres, effects that were independent of other determinants and which could predispose these children to adverse long-term health sequelae. As DNA methylation is essential for diverse biological processes such as development and cognition, and nutrition may have a major impact on the epigenome, we investigated whether DNA methylation changes arise during the course of PICU stay and remain present until PICU discharge, and whether these could be affected by the nutritional management strategy in PICU. After adjusting for pre-admission DNA methylation changes and critical illness-induced changes in cell type composition, several genes of potentially high relevance to the long-term legacy of critical illness, such as genes involved in neuronal migration, differentiation and growth, brain development and signaling, processing of amyloid-beta precursor protein, transcriptional regulation, energy metabolism and multiple cellular signalling pathways, were found to be differentially methylated between patients upon PICU discharge and matched controls. Severity of illness and early initiation of parenteral nutrition, independent of its slowing effect on recovery, were found to be significantly associated with a large proportion of the aberrant DNA methylation changes that arose during PICU stay. In a last study, we investigated whether withholding parenteral nutrition during the first week in PICU, an intervention that clearly improved short-term PICU outcome, has an impact on long-term health risks and physical and neurocognitive development. Two years after inclusion in the PEPaNIC randomised controlled trial, we assessed health risks, and physical and neurocognitive development of 786 PICU-survivors who were randomly allocated to late or early initiation of parenteral nutrition in the PICU, in comparison with 405 matched healthy children. Late initiation of parenteral nutrition did not adversely affect survival, physical and neurocognitive development, but improved overall executive functioning, more specifically inhibition, working memory, and meta-cognition. Also externalising behavioural problems and visual-motor integration were improved. Moreover, we found that omitting supplemental parenteral nutrition early during PICU stay partially normalised the long-term neurocognitive legacy of paediatric critical illness. The protective effect of withholding parenteral nutrition was most pronounced in the youngest children. In conclusion, we demonstrated that exposure to phthalates leaching from indwelling plastic medical devices could induce an attention deficit in PICU survivors. Secondly, we showed that telomeres shortened and DNA methylation changes in genes important for neurocognitive development arose during PICU stay, partly explained by early initiation of parenteral nutrition. These changes may predispose critically ill children to adverse long-term health sequelae. Finally, we found that withholding parenteral nutrition during the first week in the PICU did not negatively affect survival, growth or health status 2 years later, and significantly improved several domains of neurocognitive development, hereby partially normalising the long-term neurocognitive legacy of paediatric critical illness. Hence, these data increase our understanding of the factors and the underlying biological processes that may contribute to the impaired development of critically ill children. They will hopefully lead to a change in legislation concerning the use of plasticisers in medical devices and to a change in clinical guidelines in favour of withholding early use of PN during paediatric critical illness, both in order to improve long-term developmental outcomes of millions of PICU survivors worldwide. status: published